• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非蛋白尿型与蛋白尿型糖尿病肾病肾小球和肾小管间质组织学改变对肾脏结局的影响差异。

Differential impact of glomerular and tubule-interstitial histological changes on kidney outcome between non-proteinuric and proteinuric diabetic nephropathy.

机构信息

Department of Nephrology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan.

Department of Nephrology, Nara Prefecture Seiwa Medical Center, Nara, Japan.

出版信息

Clin Exp Nephrol. 2024 Apr;28(4):282-292. doi: 10.1007/s10157-023-02433-y. Epub 2023 Nov 29.

DOI:10.1007/s10157-023-02433-y
PMID:38019364
Abstract

BACKGROUND

Studies on kidney function and histological findings in diabetic nephropathy (DN) with low urinary protein (UP) are few. We examined the differential impact of histological changes on kidney outcomes between non-proteinuric and proteinuric DN.

METHODS

Patients diagnosed with DN by renal biopsy during 1981-2014 were divided into non-proteinuric (UP ≤ 0.5 g/day) and proteinuric (UP > 0.5 g/day) DN. The Cox proportional hazard model was used to examine the association of glomerular lesions (GLs) and interstitial fibrosis and tubular atrophy (IFTA) with end-stage kidney disease (ESKD) development after adjusting for relevant confounders.

RESULTS

The non-proteinuric and proteinuric DN groups included 197 and 199 patients, respectively. During the 10.7-year median follow-up period, 16 and 83 patients developed ESKD in the non-proteinuric and proteinuric DN groups, respectively. In the multivariable Cox hazard model, hazard ratios (HRs) [95% confidence intervals (CIs)] of GL and IFTA for ESKD in proteinuric DN were 2.94 [1.67-5.36] and 3.82 [2.06-7.53], respectively. Meanwhile, HRs [95% CIs] of GL and IFTA in non-proteinuric DN were < 0.01 [0-2.48] and 4.98 [1.33-18.0], respectively. IFTA was consistently associated with higher incidences of ESKD regardless of proteinuria levels (P for interaction = 0.49). The prognostic impact of GLs on ESKD was significantly decreased as proteinuria levels decreased (P for interaction < 0.01).

CONCLUSIONS

IFTA is consistently a useful predictor of kidney prognosis in both non-proteinuric and proteinuric DN, while GLs are a significant predictor of kidney prognosis only in proteinuric DN.

摘要

背景

患有低蛋白尿(UP)的糖尿病肾病(DN)的肾功能和组织学研究较少。我们检查了组织学变化对非蛋白尿和蛋白尿性 DN 肾脏结局的差异影响。

方法

将 1981 年至 2014 年期间通过肾活检诊断为 DN 的患者分为非蛋白尿(UP≤0.5 g/天)和蛋白尿(UP>0.5 g/天)DN。使用 Cox 比例风险模型,在校正相关混杂因素后,检查肾小球病变(GL)和间质纤维化和肾小管萎缩(IFTA)与终末期肾病(ESKD)发展的相关性。

结果

非蛋白尿和蛋白尿性 DN 组分别包括 197 例和 199 例患者。在 10.7 年的中位随访期间,非蛋白尿和蛋白尿性 DN 组分别有 16 例和 83 例患者发展为 ESKD。在多变量 Cox 风险模型中,蛋白尿性 DN 中 GL 和 IFTA 发生 ESKD 的风险比(HR)[95%置信区间(CI)]分别为 2.94[1.67-5.36]和 3.82[2.06-7.53]。同时,非蛋白尿性 DN 中 GL 和 IFTA 的 HR [95% CI]分别为<0.01[0-2.48]和 4.98[1.33-18.0]。无论蛋白尿水平如何,IFTA 均与更高的 ESKD 发生率相关(P 交互作用=0.49)。随着蛋白尿水平的降低,GL 对 ESKD 的预后影响显著降低(P 交互作用<0.01)。

结论

IFTA 始终是非蛋白尿和蛋白尿性 DN 肾脏预后的有用预测指标,而 GL 仅在蛋白尿性 DN 中是肾脏预后的重要预测指标。

相似文献

1
Differential impact of glomerular and tubule-interstitial histological changes on kidney outcome between non-proteinuric and proteinuric diabetic nephropathy.非蛋白尿型与蛋白尿型糖尿病肾病肾小球和肾小管间质组织学改变对肾脏结局的影响差异。
Clin Exp Nephrol. 2024 Apr;28(4):282-292. doi: 10.1007/s10157-023-02433-y. Epub 2023 Nov 29.
2
Prognostic value of metabolic syndrome in renal structural changes in type 2 diabetes.代谢综合征对 2 型糖尿病患者肾脏结构变化的预测价值。
Int Urol Nephrol. 2022 Aug;54(8):2005-2014. doi: 10.1007/s11255-021-03051-x. Epub 2022 Jan 19.
3
Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy.2型糖尿病合并显性蛋白尿性糖尿病肾病患者估计肾小球滤过率下降的临床和病理预测因素
Diabetes Metab Res Rev. 2015 Sep;31(6):572-81. doi: 10.1002/dmrr.2633. Epub 2015 Mar 5.
4
Validation of the interstitial fibrosis and tubular atrophy on the new pathological classification in patients with diabetic nephropathy: A single-center study in China.糖尿病肾病患者新病理分类中肾小管间质纤维化和肾小管萎缩的验证:一项中国单中心研究
J Diabetes Complications. 2016 Apr;30(3):537-41. doi: 10.1016/j.jdiacomp.2015.12.002. Epub 2015 Dec 8.
5
Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-β-d-Glucosaminidase, and Urinary β2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy.2型糖尿病合并经活检证实的糖尿病肾病患者肾小管间质病变、尿N-乙酰-β-D-氨基葡萄糖苷酶及尿β2-微球蛋白的预后价值
Clin J Am Soc Nephrol. 2016 Apr 7;11(4):593-601. doi: 10.2215/CJN.04980515. Epub 2016 Jan 22.
6
Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy.血清可溶性尿激酶型纤溶酶原激活物受体作为糖尿病肾病肾损伤严重程度的潜在生物标志物。
Diabetes Res Clin Pract. 2021 Dec;182:109116. doi: 10.1016/j.diabres.2021.109116. Epub 2021 Oct 30.
7
A retrospective cohort study on the pathology and outcomes of type 2 diabetic patients with renal involvement.回顾性队列研究:2 型糖尿病伴肾损害患者的病理与结局。
Int Urol Nephrol. 2021 Feb;53(2):333-341. doi: 10.1007/s11255-020-02657-x. Epub 2020 Oct 6.
8
Plasma D-dimer levels are associated with disease progression in diabetic nephropathy: a two-center cohort study.血浆 D-二聚体水平与糖尿病肾病的疾病进展相关:一项两中心队列研究。
Ren Fail. 2023;45(2):2285868. doi: 10.1080/0886022X.2023.2285868. Epub 2023 Nov 27.
9
Renal histology in diabetic nephropathy predicts progression to end-stage kidney disease but not the rate of renal function decline.糖尿病肾病的肾组织学改变可预测进展为终末期肾病,但不能预测肾功能下降的速度。
BMC Nephrol. 2020 Jul 18;21(1):285. doi: 10.1186/s12882-020-01943-1.
10
Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy.糖尿病性视网膜病变可能预测糖尿病肾病患者的肾脏结局。
Ren Fail. 2018 Nov;40(1):243-251. doi: 10.1080/0886022X.2018.1456453.

引用本文的文献

1
Shenyuan granules improve cellular senescence through Klotho-mediated p16/p21 signaling pathway in diabetic kidney disease.参元颗粒通过Klotho介导的p16/p21信号通路改善糖尿病肾病中的细胞衰老。
Front Med (Lausanne). 2025 Jul 31;12:1627412. doi: 10.3389/fmed.2025.1627412. eCollection 2025.
2
New interpretation of diabetic nephropathy or diabetic kidney disease from kidney biopsy: review article.肾活检对糖尿病肾病的新解读:综述文章
Clin Exp Nephrol. 2025 Mar 24. doi: 10.1007/s10157-025-02661-4.

本文引用的文献

1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
2
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.甾体和非甾体盐皮质激素受体拮抗剂在心脏肾脏医学中的应用。
Eur Heart J. 2021 Jan 7;42(2):152-161. doi: 10.1093/eurheartj/ehaa736.
3
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
钠-葡萄糖协同转运蛋白2(SGLT2)抑制通过促进酮体诱导的哺乳动物雷帕霉素靶蛋白复合体1(mTORC1)抑制介导对糖尿病肾病的保护作用。
Cell Metab. 2020 Sep 1;32(3):404-419.e6. doi: 10.1016/j.cmet.2020.06.020. Epub 2020 Jul 28.
4
Renal arteriolar hyalinosis, not intimal thickening in large arteries, is associated with cardiovascular events in people with biopsy-proven diabetic nephropathy.肾小动脉玻璃样变,而非大动脉内膜增厚,与经活检证实的糖尿病肾病患者的心血管事件相关。
Diabet Med. 2020 Dec;37(12):2143-2152. doi: 10.1111/dme.14301. Epub 2020 May 7.
5
Nonproteinuric diabetic kidney disease.非蛋白尿型糖尿病肾病。
Clin Exp Nephrol. 2020 Jul;24(7):573-581. doi: 10.1007/s10157-020-01881-0. Epub 2020 Mar 31.
6
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.依格列净(CS-3150)治疗伴微量白蛋白尿的 2 型糖尿病的疗效和安全性:一项随机、双盲、安慰剂对照、Ⅱ期临床试验。
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1161-1172. doi: 10.2215/CJN.14751218. Epub 2019 Jun 27.
7
Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study.非蛋白尿型与蛋白尿型糖尿病肾病:一项基于全国性、基于活检队列研究的倾向评分匹配分析。
Diabetes Care. 2019 May;42(5):891-902. doi: 10.2337/dc18-1320. Epub 2019 Mar 4.
8
Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells.解析 SGLT2 抑制在人近端肾小管细胞中的肾保护作用。
Am J Physiol Renal Physiol. 2019 Mar 1;316(3):F449-F462. doi: 10.1152/ajprenal.00431.2018. Epub 2018 Dec 12.
9
Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.中国 2 型糖尿病患者的糖尿病肾病进展和肾功能下降轨迹。
Kidney Int. 2019 Jan;95(1):178-187. doi: 10.1016/j.kint.2018.08.026. Epub 2018 Nov 8.
10
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease.糖尿病相关的慢性肾脏病:糖尿病性肾脏疾病与非糖尿病性肾脏疾病。
Nat Rev Nephrol. 2018 Jun;14(6):361-377. doi: 10.1038/s41581-018-0001-y.